Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHESS: Durvalumab, Chemotherapy, and SBRT in Oligo-metastatic NSCLC
NCT03965468Phase 2Active, not recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2019
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-Free Survival at 12 months. Started Nov 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03965468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965468.